Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent

Authors: Adolfo Varona, Lorena Blanco, Itxaro Perez, Javier Gil, Jon Irazusta, José I López, M Luz Candenas, Francisco M Pinto, Gorka Larrinaga

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Cell-surface glycoproteins play critical roles in cell-to-cell recognition, signal transduction and regulation, thus being crucial in cell proliferation and cancer etiogenesis and development. DPP IV and NEP are ubiquitous glycopeptidases closely linked to tumor pathogenesis and development, and they are used as markers in some cancers. In the present study, the activity and protein and mRNA expression of these glycoproteins were analysed in a subset of clear-cell (CCRCC) and chromophobe (ChRCC) renal cell carcinomas, and in renal oncocytomas (RO).

Methods

Peptidase activities were measured by conventional enzymatic assays with fluorogen-derived substrates. Gene expression was quantitatively determined by qRT-PCR and membrane-bound protein expression and distribution analysis was performed by specific immunostaining.

Results

The activity of both glycoproteins was sharply decreased in the three histological types of renal tumors. Protein and mRNA expression was strongly downregulated in tumors from distal nephron (ChRCC and RO). Moreover, soluble DPP IV activity positively correlated with the aggressiveness of CCRCCs (higher activities in high grade tumors).

Conclusions

These results support the pivotal role for DPP IV and NEP in the malignant transformation pathways and point to these peptidases as potential diagnostic markers.
Appendix
Available only for authorised users
Literature
1.
Bannasch P, Zerban H: Animal models and renal carcinogenesis. Tumors and tumorlike conditions of the kidneys and ureters. Edited by: Eble JN. 1990, New York: Churchill-Livingstone, 1-34.
2.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed
3.
López-Beltrán A, Scarpelli M, Montironi R, Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006, 49: 798-805. 10.1016/j.eururo.2005.11.035.CrossRefPubMed
4.
Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH: Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol. 2006, 13: 573-580. 10.1111/j.1442-2042.2006.01353.x.CrossRefPubMed
5.
Patraki E, Cardillo MR: Quantitative immunohistochemical analysis of matrilysin 1 (MMP-7) in various renal cell carcinoma subtypes. Int J Immunopathol Pharmacol. 2007, 20: 697-705.PubMed
6.
Pro B, Dang NH: CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol. 2004, 19: 1345-1351.PubMed
7.
Sumitomo M, Shen R, Nanus D: Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta. 2005, 1751: 52-59.CrossRefPubMed
8.
Raguin O, Fournié-Zaluski MC, Romieu A, Pèlegrin A, Chatelet F, Pélaprat D, Barbet J, Roques BP, Gruaz-Guyon A: A labeled Neutral Endopeptidase Inhibitor as a potential tool for tumor diagnosis and prognosis. Angew Chem Int Ed. 2005, 44: 4058-4061. 10.1002/anie.200500700.CrossRef
9.
Busek P, Malík R, Sedo A: Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 2004, 36: 408-421. 10.1016/S1357-2725(03)00262-0.CrossRefPubMed
10.
Santos RAS, Ferreira AJ, Simoes e Silva AC: Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol. 2008, 93: 519-527. 10.1113/expphysiol.2008.042002.CrossRefPubMed
11.
Kelly T: Fibroblast interaction protein-α and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signalling and are potential targets for cancer therapy. Drug Resist Updat. 2005, 8: 51-58. 10.1016/j.drup.2005.03.002.CrossRefPubMed
12.
Varona A, Blanco L, López JI, Gil J, Agirregoitia E, Irazusta J, Larrinaga G: Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol-Renal Physiol. 2007, 292: F780-F788. 10.1152/ajprenal.00148.2006.CrossRefPubMed
13.
Blanco L, Larrinaga G, Pérez I, López JI, Gil J, Agirregoitia E, Varona A: Acid, basic and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. Am J Physiol-Renal Physiol. 2008, 294: F850-F858. 10.1152/ajprenal.00469.2007.CrossRefPubMed
14.
Sobin LH, Wittekind C: TNM Classification of Malignant Tumors. 2002, New York: Wiley-Liss, 6
15.
Furhman SA, Lasky LC, Limas : Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982, 6: 655-663. 10.1097/00000478-198210000-00007.CrossRef
16.
Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF: A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem. 1995, 270: 14107-14. 10.1074/jbc.270.23.14107.CrossRefPubMed
17.
Liu WJ, Hansen PJ: Progesterone-induced secretion of dypeptidyl peptidase-IV (cluster differentiation antigen-26) by the uterine endometrium of the ewe and cow that costimulates lymphocyte proliferation. Endocrinology. 1995, 136: 779-87. 10.1210/en.136.2.779.PubMed
18.
Florentin D, Sassi A, Roques BP: A highly sensitive fluorimetric assay for "enkephalinase", a neutral metalloendopeptidase that releases Tyr-Gly-Gly from enkephalins. Anal Biochem. 1984, 141: 62-69. 10.1016/0003-2697(84)90425-1.CrossRefPubMed
19.
Patak E, Candenas ML, Pennefather JN, Ziccone S, Lilley A, Martín JD, Flores C, Mantecón AG, Pinto FM: Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol. 2003, 139: 523-532. 10.1038/sj.bjp.0705279.CrossRefPubMedPubMedCentral
20.
Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2003, 132: 365-368.
21.
Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K: In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol. 2007, 8: 47-60. 10.1186/1471-2199-8-47.CrossRefPubMedPubMedCentral
22.
Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A: Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004, 313: 856-862. 10.1016/j.bbrc.2003.11.177.CrossRefPubMed
23.
Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML: mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol. 2004, 494: 233-239. 10.1016/j.ejphar.2004.05.016.CrossRefPubMed
24.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 18: 1-11.
25.
Carl-McGrath S, Lendeckel U, Ebert M, Röcken C: Ectopeptidases in tumour biology: A review. Histol Histopathol. 2006, 21: 1339-1353.PubMed
26.
Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH: The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008, 13: 1634-1645. 10.2741/2787.CrossRefPubMed
27.
Bauvois B: Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?. Oncogene. 2004, 23: 317-329. 10.1038/sj.onc.1207124.CrossRefPubMed
28.
Larrinaga G, Lopez JI, Casis L, Blanco L, Gil J, Agirregoitia E, Varona A: Cystinyl aminopeptidase activity is decreased in renal cell carcinomas. Regul Pept. 2007, 144: 56-61. 10.1016/j.regpep.2007.06.002.CrossRefPubMed
29.
Avery AK, Beckstead J, Renshaw JJ, Corless CL: Use of antibodies to RCC and CD10 in the differential diagnosis of Renal Neoplasms. Am J Surg Pathol. 2000, 24: 203-210. 10.1097/00000478-200002000-00006.CrossRefPubMed
30.
Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R: CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology. 2004, 45: 460-467. 10.1111/j.1365-2559.2004.01982.x.CrossRefPubMed
31.
Zhou M, Roma A, Magi-Galluzzi C: The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005, 25: 247-257. 10.1016/j.cll.2005.01.004.CrossRefPubMed
32.
Martignoni G, Pea M, Brunelli M, Chilosi M, Zamó A, Bertaso M, Cossu-Rocca P, Eble JN, Mikuz G, Puppa G, Badoual C, Ficarra V, Novella G, Bonetti F: CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol. 2004, 17: 1455-1463. 10.1038/modpathol.3800236.CrossRefPubMed
33.
Droz D, Zachar D, Charbit L, Gogusev J, Chrétein Y, Iris L: Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol. 1990, 137: 895-905.PubMedPubMedCentral
34.
Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tchibana M, Katsuoka Y, Dang NH, Morimoto C: Anti-CD26 monoclonal antibody-mediated G1-S arrest on human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res. 2006, 12: 3470-3477. 10.1158/1078-0432.CCR-06-0361.CrossRefPubMed
35.
Wesley U, Albino AP, Tiwari S, Houghton AN: A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med. 1999, 190: 311-322. 10.1084/jem.190.3.311.CrossRefPubMedPubMedCentral
36.
Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S: Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta. 2005, 1751: 45-51.CrossRefPubMed
37.
Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF: A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem. 1995, 270: 14107-14. 10.1074/jbc.270.23.14107.CrossRefPubMed
38.
Olivo Rdo A, Teixeira Cde F, Silveira PF: Representative aminopeptidases and prolyl endopeptidase from murine macrophages: comparative activity levels in resident and elicited cells. Biochem Pharmacol. 2005, 69: 1441-1450. 10.1016/j.bcp.2005.03.002.CrossRefPubMed
39.
Cordero OJ, Ayude D, Nogueira M, Rodríguez-Berrocal FJ, de La Cadena MP: Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 2000, 83: 1139-1146. 10.1054/bjoc.2000.1410.CrossRefPubMedPubMedCentral
40.
Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP: Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Tumour Biol. 2006, 27: 1-7. 10.1159/000090150.CrossRefPubMed
41.
Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 1998, 4: 50-57. 10.1038/nm0198-050.CrossRefPubMed
42.
Göhring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J, Riemann D: Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med. 1998, 2: 409-414.PubMed
43.
Goodman OB, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL, Nanus DM: Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem. 2006, 281: 33597-33605. 10.1074/jbc.M602490200.CrossRefPubMed
44.
Metadata
Title
Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent
Authors
Adolfo Varona
Lorena Blanco
Itxaro Perez
Javier Gil
Jon Irazusta
José I López
M Luz Candenas
Francisco M Pinto
Gorka Larrinaga
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-193

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study

Research article

Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer

Research article

Factors associated with cancer-related fatigue in breast cancer patients undergoing endocrine therapy in an urban setting: a cross-sectional study

Research article

Novel genetic variants in miR-191 gene and familial ovarian cancer

Research article

Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells

Research article

Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits